Related references
Note: Only part of the references are listed.Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
Elena Galvani et al.
NATURE COMMUNICATIONS (2020)
A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy
Balamayoora Theivanthiran et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Effect of post-implant exercise on tumour growth rate, perfusion and hypoxia in mice
Linda A. Buss et al.
PLOS ONE (2020)
Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression
Hye Suk Hwang et al.
CELLS (2020)
Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma
Saeed Daneshmandi et al.
CANCERS (2019)
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
Jasmine Davda et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1
Marine Leclerc et al.
NATURE COMMUNICATIONS (2019)
Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity
Kathleen M. Kokolus et al.
ONCOIMMUNOLOGY (2019)
Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model
Alvaro Padron et al.
EXPERIMENTAL GERONTOLOGY (2018)
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
Todd A. Triplett et al.
NATURE BIOTECHNOLOGY (2018)
Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors
Erika J. Crosby et al.
ONCOIMMUNOLOGY (2018)
Anti PD-1 treatment increases [18F]FDG uptake by cancer cells in a mouse B16F10 melanoma model
Mayu Tomita et al.
EJNMMI RESEARCH (2018)
Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
Bogang Wu et al.
ONCOIMMUNOLOGY (2018)
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Olivier De Henau et al.
NATURE (2016)
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
Rony Dahan et al.
CANCER CELL (2015)
Small Amounts of Sub-Visible Aggregates Enhance the Immunogenic Potential of Monoclonal Antibody Therapeutics
Maryam Ahmadi et al.
PHARMACEUTICAL RESEARCH (2015)
Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
Shihao Chen et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Share Paper
